Showing results (131-140 of 190) with videos related to

Sort By:
Pageof 19
Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapyAndrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical and Translational Science|August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaLilit Karapetyan, Anthony R Cillo, Shuaichao Wang, et al.
Clinical Epigenetics|July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomasJonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Pigment Cell & Melanoma Research|August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeuticsJason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Pageof 19